Looking at top Wall Street opinions, Bristol-Myers Squibb Company (NYSE: BMY) has recently made its way into the research list of Societe Generale – signaling that their analyst’s rating adjustment is noteworthy. This stock was upgraded to a rating of Buy in the eyes of Societe Generale, whereas its previous rating was Sell in the eyes of Societe Generale, as reported on Tuesday, January 15th, 2019. Another heavy-hitting research note was published by Citigroup on Monday October 22nd, 2018, with this firm downgrading BMY to an updated rating of Neutral from its previous rating of Buy. In the past six months and three months of trading, shares of Bristol-Myers Squibb Company (BMY) have moved by -17.83% and -5.09%, respectively.
Brokerage Updates Related to Bristol-Myers Squibb Company (BMY) Stock
This publicly-traded organization generated losses of -6.36% over the last 5 sessions. Right now, this stock is the subject of 14 analysts’ evaluations, who – on average – have given this company’s shares a Buy rating. Not a Single analyst have given underperform rating or sell rating, and 4 have given a rating of Buy or better. Based on the 14 stock market experts following this company, the average 12-month price target is $56.73. Moreover, individual price targets range between $52.00-$62.00. With its recent move to $55.00, we can see that these firms project this stock will loss by -25.82% in one year.
Updates from Bristol-Myers Squibb Company (BMY) SEC Form 4
This particular company’s shares have garnered a lot of attention in recent days, as insiders are unloading their holdings while having generated a 0.10% rise since the beginning of the calendar year. A Director at Bristol-Myers Squibb Company (BMY) bought some of its shares in a transaction that was finalized on Apr 30.
Bristol-Myers Squibb Company (NYSE:BMY) Results in the Pipeline
The next scheduled release of financial results for Bristol-Myers Squibb Company will be for the Dec-18 quarter. As it stands right now, market analysts are anticipating the per-share earnings for the three-month period will be $0.85. In the same vein, they expect sales for the quarter to amount to $5,985.40 million.
Now let’s turn to earnings surprise history: in the most recent quarter, the company reported about $5,973.00 million in revenue alongside EPS at $0.94. On average, the analyst projection was calling for $5,691.00 million with $1.09 per share in earnings, respectively. In the preceding quarter, this company’s revenue reached $5,704.00 million, with earnings per share ending up at $1.01.
Celgene Corporation (NASDAQ:CELG) experienced a gain of 0.40% from the closing price in the previous trading day. That boost the price to $85.60 per share, as observed on March 12th, 2019, at a time when the total trading volume reached 8,449,707 shares of stock – compared to the typical average of 11.38M shares per day (as recorded over the past three months). The consensus estimate for these shares has been shifted to $97.66.
Pricing Indications for Celgene Corporation (CELG)
This organization has had a price-to-earnings ratio of 15.47 in the last year. In the most recent trading session, the daily high was $86.28, bringing the per-share value 0.40% high its 52-week high and about -10.18% more expensive than its 52-week low. Meanwhile, it gained 86.13 from its observable 50-day simple moving average. Right at this moment, the per-share value is 4.20% higher than the mean per-share price over the last 200 days in the market.
Celgene Corporation (NASDAQ:CELG) In-Depth Brokerage Insights
We can see that a number of brokerage firms are putting their focus onto this stock. Out of this group, 0 have a sell rating, 6 have a Buy rating, 3 have an outperform rating, while 12 provided a Hold rating for these shares – thanks to data from Thomson Reuters I/B/E/S. Additionally, 0 have recommended that these shares are an Underperforming investment. The current consensus recommendation is at 2.40, based on information from Thomson Reuters.
CELG Stock Value Potential
In trading activity as of late, this stock’s value was 82.19 up from its 200 day moving average, while also -0.08% down when compared against its 50-day simple moving average. Over the course of the past year of trading, the share price stuck in the range of $84.00-$106.00. The market value for the entire organization reached 61.02B. After the trading day started off at the price of $85.60, these shares nearly bottomed out at its low price of $85.09 and nearly peaked at $86.28 as its full-day high price. In the last trading session, the price ended the day at $85.26. The institutional holdings related to this organization account for 0.10%, and the Beta factor is now 1.68. This company’s RSI (Relative Strength Index) managed to hit 44.12.
Celgene Corporation (NASDAQ:CELG) Analyst Points of Focus
Celgene Corporation (CELG) has found itself inside of Jefferies’s research list, so their analyst rating adjustment is worth taking note of. This stock was downgraded to Hold, compared to its previous rating of Buy by Jefferies, as garnered from a news report on Friday February 1st, 2019. An additional helpful research note was sent out by Robert W. Baird’s on Friday January 4th, 2019. The brokerage decided to upgrade CELG to Outperform from its previous rating of Neutral.